Epigenetics is a broad term. And this was a rather generic article. They are primarly discussing products, technologies and applications in the R&D end of things. This is not so much an article on pharmaceutical drug development. There is no mention of BET inhibitors here, or any of the companies with BET inhibitors currently or soon to be in clinical trials. So the omission of RVX and Zenith from this article means nothing.
BearDownAZ